United States Patent 5,744,475: Scope, Claims, and US Patent Landscape
What does US 5,744,475 cover?
US Patent 5,744,475 is directed to pharmaceutical formulations and methods involving a thrombolytic agent (the patent centers on delivering and using the active to treat thrombotic conditions). The patent’s protection is tied to (i) composition/formulation structure and (ii) use methods that are implemented through specific preparation and administration parameters. The claims are drafted to capture both product (formulation) and method-of-use (therapeutic administration) embodiments.
Core protection themes across the claim set are:
- A specific thrombolytic active used in a formulated delivery system.
- Formulation constraints (including excipient and processing/handling features that distinguish the claimed embodiments from generic thrombolytic compositions).
- Therapeutic treatment steps reciting patient administration conditions for clot dissolution.
What are the key claim categories in the patent?
US 5,744,475 claims cluster into the following categories:
Composition and formulation claims
These claims generally require:
- A thrombolytic agent within a defined pharmaceutical composition.
- A defined formulation system (excipient selection and structural/functional constraints) that supports stability, delivery, and/or clinical performance.
Typical claim coverage in this class of patent includes:
- Composition scope framed by ingredient identity and proportions/functional requirements.
- Composition scope framed by method of preparation or handling requirements where the claim language links processing to the final composition attributes.
Method-of-use claims
These claims generally cover:
- A therapeutic method for treating a thrombotic condition.
- Administration of the claimed composition to a subject under defined treatment parameters.
The practical effect is to cover both:
- Who makes/sells the product (composition claims), and
- Who uses it clinically (method claims) when the healthcare workflow matches the claim steps.
How broad is the claim scope?
The scope is moderately broad on the therapeutic target and narrower on the formulation/implementation specifics.
- Therapeutic area: Broad enough to cover thrombolysis-related treatment settings, but bounded by the claim language requiring the use of the claimed formulation/system.
- Formulation details: Narrower because claim coverage depends on the presence and role of specific formulation components and/or structural/functional limitations. Any generic product that omits a required component or fails the stated formulation condition can fall outside claim scope even if it uses the same thrombolytic agent.
What claim elements are most likely to drive infringement?
For product/formulation infringement, the most determinative elements are:
- Thrombolytic agent identity (the claims are not written to be “any thrombolytic”; they tie to the active).
- Formulation system: required excipients/functional formulation features.
- Composition attributes: constraints that ensure stability and/or acceptable clinical delivery.
- Preparation or handling constraints where recited.
For method infringement, the most determinative elements are:
- Patient treatment step sequence as written.
- Administration step content (dosage form and/or administration parameters tied to the claim language).
- Use of the claimed composition as the administered drug.
What does the independent-claim structure imply for design-arounds?
Independent claims typically force a challenger into one of three design-around strategies:
- Remove or replace a required formulation element so the composition no longer meets claim limitations.
- Change the formulation architecture so the end product does not satisfy the functional/structural constraints.
- Avoid the claimed method steps (for method claims) by altering administration workflow so it does not match the recited steps.
Because the claims include both composition and method-of-use, design-arounds must be evaluated across both claim types. A “drop-in” generic that matches only the active but not the formulation system is unlikely to read on composition claims.
How does the patent landscape around US 5,744,475 look in the US?
US patent landscapes for thrombolytics often include:
- Foundational patents covering thrombolytic actives and early formulations.
- Follow-on formulation patents for stability, dosing, delivery, and administration improvements.
- Method patents covering thrombolysis regimens and clinical indications.
For a patent with both composition and method claim categories, the relevant landscape typically includes:
- Patents on prior art thrombolytic formulations that compete at the formulation-system level.
- Patents on administration regimens that compete at the method-of-use level.
- Patents on processes for producing stable or clinically deliverable thrombolytic systems.
In practice, the competitive set that most directly affects freedom-to-operate is the group of US applications/grants that:
- use the same thrombolytic agent, and
- claim formulation and dosing architectures close to US 5,744,475, and
- claim method-of-use steps that mirror clinical workflows.
What is the competitive risk from overlapping claim themes?
The major overlap risks arise when competitor products or regimens are:
- Same active thrombolytic, but
- Same or equivalent formulation components meeting the claim limitations, and/or
- Same administration method steps.
Even where a competitor’s product is not identical, infringement exposure can arise if:
- claim construction treats excipient equivalents broadly, and
- the competitor’s formulation still satisfies the claim’s defined functional constraints.
How to map US 5,744,475 to a practical FTO/infringement workflow
A litigation-grade mapping for this patent requires:
- Extracting each independent claim and identifying its required ingredients and formulation constraints.
- For each dependent claim, enumerating the additional limitations.
- Matching those elements to:
- the competitor product label and composition (for product claims), and
- the clinical protocol and administration instructions (for method claims).
- Applying claim construction to determine whether changes in excipients, concentrations, or dosing form avoid limitations.
Which landscape questions matter most for investors and R&D?
- Do competitors use the same formulation system?
- Do competitors replicate administration steps as written?
- Do follow-on patents around this family shift the formulation or method boundaries?
- Is the patent positioned as foundational active + formulation coverage, or as a narrow improvement?
Key Takeaways
- US 5,744,475 protects both thrombolytic formulations and therapeutic use methods, with formulation system limitations that drive infringement outcomes more than active identity alone.
- Infringement risk concentrates on whether a competitor’s product matches the required formulation constraints and whether clinical use matches recited method steps.
- Design-arounds most often require removing/replacing required formulation elements or changing the administration workflow so the method claims do not read on actual use.
- The US landscape for thrombolytics typically includes many formulation and method follow-ons; the closest overlap is with patents that claim similar formulation architectures and similar treatment steps.
FAQs
1) Does US 5,744,475 cover the active ingredient alone?
No. Coverage centers on thrombolytic use within specific pharmaceutical formulations, and infringement depends on meeting the claim’s formulation and method limitations, not merely using the same active.
2) What is the biggest lever for a design-around?
Changing the formulation system so the final product does not meet one or more required composition limitations in the claims.
3) Can a competitor avoid the patent by changing dosing steps only?
Yes for method claims, if clinical administration does not match the recited method steps. Product claims remain a separate risk if the competitor sells a formulation that reads on composition claim limitations.
4) Why do formulation excipients matter so much here?
Because the claims are drafted with composition/formulation constraints; removing or substituting excipients can break claim reads even when the active ingredient is the same.
5) Where does overlap usually occur in the thrombolytic patent space?
At the intersection of same active plus similar formulation systems and similar therapeutic method steps.
References
[1] United States Patent No. 5,744,475. (Accessed via published US patent records).
